T. Rowe Price Investment Management, Inc. Immunome Inc. Call Options Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMNM
# of Institutions
118Shares Held
43.7MCall Options Held
67.2KPut Options Held
65.9K-
Redmile Group, LLC San Francisco, CA4.89MShares$65.1 Million3.86% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA3.88MShares$51.7 Million1.66% of portfolio
-
Black Rock Inc. New York, NY3.76MShares$50.1 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X03.16MShares$42.1 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.92MShares$38.9 Million0.0% of portfolio
About Immunome Inc.
- Ticker IMNM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 12,127,400
- Market Cap $162M
- Description
- Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...